Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Feb 25, 2026
Why Diageo (DEO) Just Crashed -15%: Dividend Cut, Weak Sales, and a Deep Reset

Why Diageo (DEO) Just Crashed -15%: Dividend Cut, Weak Sales, and a Deep Reset

DEO (Diageo) is down more than 15% today because it cut its sales guidance again, halved its dividend, and showed ongoing weakness in key markets like the U.S. and China in its latest half‑year results.

Why DEO fell over 15%

  • For the first half of fiscal 2026, organic net sales and adjusted EPS both declined about 3% year over year and missed analyst expectations, with U.S. spirits and Chinese white spirits particularly weak.

  • Management cut full‑year 2026 guidance again, now expecting organic sales to fall 2–3% and organic operating profit to be flat to up only low single digits, versus a prior outlook of flat to slightly down sales and low‑ to mid‑single‑digit profit growth.

  • Diageo also slashed its interim dividend by about 50% (to 20 cents per share) and reset its payout ratio, saying the cut is needed to strengthen the balance sheet and gain flexibility, which markets took as a “sucker punch” on top of weak results.

Demand headwinds worrying investors

  • U.S. sales fell roughly 7–9%, with tequila brands like Don Julio down more than 20% as American consumers trade down to cheaper options and overall spirits demand softens.

  • Asia Pacific, including China, also declined double digits, and management highlighted broader structural headwinds: affordability pressures, rising health‑conscious moderation, GLP‑1 weight‑loss drugs dampening alcohol consumption, and competition from alternatives like cannabis.

  • Coming right after a brief rebound in the shares, these “deep reset” signals from the new CEO convinced investors that the turnaround will be slower and more painful than hoped, driving a sharp de‑rating and a 15%+ single‑day drop.

  • Tickeron AI Perspective

     Disclaimers and Limitations

Related Ticker: DEO

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


DEO in downward trend: price dove below 50-day moving average on September 08, 2026

DEO moved below its 50-day moving average on September 08, 2026 date and that indicates a change from an upward trend to a downward trend. In 31 of 45 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 69%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for DEO turned negative on August 18, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 22 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 49%.

The 10-day moving average for DEO crossed bearishly below the 50-day moving average on September 15, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 56%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where DEO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 60%.

The Aroon Indicator for DEO entered a downward trend on September 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 30 of 63 cases where DEO's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 48%.

The Momentum Indicator moved above the 0 level on September 22, 2026. You may want to consider a long position or call options on DEO as a result. In 48 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 56%.

The 50-day moving average for DEO moved above the 200-day moving average on August 19, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a +2.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where DEO advanced for three days, in 117 of 275 cases, the price rose further within the following month. The odds of a continued upward trend are 43%.

DEO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 22 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.403) is normal, around the industry mean (5.115). P/E Ratio (27.635) is within average values for comparable stocks, (97.629). Projected Growth (PEG Ratio) (0.540) is also within normal values, averaging (0.651). Dividend Yield (0.038) settles around the average of (0.028) among similar stocks. P/S Ratio (2.469) is also within normal values, averaging (4.786).

The Tickeron PE Growth Rating for this company is 22 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 52 (best 1 - 100 worst), indicating steady price growth. DEO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DEO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 100, placing this stock worse than average.

Industry description

The alcoholic beverage market includes beer, wine, and spirits. From $230 billion in 2015, the industry has grown to around $250 billion by 2019. In recent years, alcoholic beverage makers have been looking to expand distribution and purchase channels, such as through online stores (e.g. e-commerce platform Drizly) and convenience stores. Anheuser-Busch In Bev and Diageo are major global alcoholic beverage companies, while U.S.-owned companies include Constellation Brands and Brown-Forman Corp. among several others.

Market Cap

The average market capitalization across the Beverages: Alcoholic Industry is 5.45B. The market cap for tickers in the group ranges from 3.75K to 14.38T. PBGDF holds the highest valuation in this group at 14.38T. The lowest valued company is SRSG at 3.75K.

High and low price notable news

The average weekly price growth across all stocks in the Beverages: Alcoholic Industry was 2%. For the same Industry, the average monthly price growth was -11%, and the average quarterly price growth was -14%. WVVIP experienced the highest price growth at 13%, while MGPI experienced the biggest fall at -10%.

Volume

The average weekly volume growth across all stocks in the Beverages: Alcoholic Industry was -33%. For the same stocks of the Industry, the average monthly volume growth was 11% and the average quarterly volume growth was -62%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 47
P/E Growth Rating: 56
Price Growth Rating: 69
SMR Rating: 97
Profit Risk Rating: 100
Seasonality Score: -56 (-100 ... +100)
View a ticker or compare two or three
DEO
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a producer of wine, beer and other beverages

Industry BeveragesAlcoholic

Industry
Beverages Alcoholic
Address
16 Great Marlborough Street
Phone
+44 2079479100
Employees
27938
Web
https://www.diageo.com
Interact to see
Advertisement
INSM shares are surging approximately +10% in premarket trading on Monday, March 23, 2026, from a prior close of $136.00, placing the premarket price near $149.60. The primary catalyst is the release of positive topline results from the Phase 3 ENCORE trial of ARIKAYCE® in patients with newly diagnosed or recurrent MAC (Mycobacterium avium complex) lung disease — a readout Insmed had flagged as expected in "March or April 2026".
CF shares are trading approximately -6% lower in Monday's premarket session, dropping from a Friday close of $124.90 to approximately $117.41. Primary catalyst: President Trump announced a five-day pause on strikes against Iranian energy infrastructure following "very good" diplomatic signals, triggering a sharp unwind of the geopolitical risk premium embedded in fertilizer stocks.
APGE shares surged approximately 16% in premarket trading on March 23, 2026, after the company announced positive 52-week data from Part A of its Phase 2 APEX clinical trial. The primary catalyst is a highly anticipated clinical readout showing that zumilokibart (APG777) delivered durable and deepening responses in patients with moderate-to-severe atopic dermatitis at both every 3-month and 6-month dosing intervals.
Shares of VALN are plummeting approximately 35% in Monday's session, from a Friday close of $10.66 to roughly $6.93, in heavy volume trading. The primary catalyst is the release of Phase 3 VALOR trial topline results for Valneva's Lyme disease vaccine candidate, co-developed with PFE (Pfizer) — results that showed strong clinical efficacy but failed to meet the pre-determined statistical criterion for the primary endpoint.
AXTI is surging approximately +11.00% in Monday's session, trading near $60.21, up from a prior closing price of $54.24. The move extends the stock's post-earnings rally that began last Thursday when shares jumped more than 19% following AXT's Q4 2025 results.
Tower Semiconductor (TSEM) shares are surging approximately +10% intraday on Monday, March 23, trading around $180, up from the previous close of $163.63 on March 20, 2026. The primary catalyst is the opening day of APEC 2026 in San Antonio, Texas, where Tower Semiconductor is presenting its newly unveiled Gen3 BCD power management platform designed to address escalating AI data center power demands.
CD is indicated down about 17% in premarket trading after the latest completed session, pointing to a sharp negative market reaction heading into the open. The stock’s weakness comes against a backdrop of lingering uncertainty following its privatization and delisting process from Nasdaq, which has left limited liquidity and a thinner news flow around the name.
SEDG is indicated down roughly 9% in premarket trading, following a strong advance in the prior regular session. The pullback comes after shares rallied on optimism around new product launches and an analyst upgrade, leaving the stock vulnerable to profit-taking and volatility.
NTGR shares surged approximately 11% in premarket trading on March 24, 2026, building on a roughly 20% overnight jump in the prior session. The primary catalyst is a landmark Federal Communications Commission (FCC) ruling that prohibits all imports of consumer routers manufactured overseas, citing national security concerns.
ANNA is surging approximately +20.00% in Tuesday's premarket session, rebounding sharply from Monday's -22.84% decline. The primary catalyst remains the ongoing U.S.-Iran military conflict, which disrupted Qatari LNG exports and drove European benchmark natural gas prices to multi-year highs.
Concentrix Corporation (CNXC) shares are falling approximately 11% in Tuesday's premarket session after the company released its fiscal Q1 2026 earnings report before market open. Adjusted diluted EPS came in at $2.61, missing the Wall Street consensus estimate of approximately $2.64.
Shares of Karyopharm Therapeutics (KPTI) are trading approximately 12% lower in Tuesday's premarket session, with the previous close at $7.63. The primary catalyst is the March 24 release of topline Phase 3 SENTRY trial data, in which the company met only one of two co-primary endpoints.
IBRX shares are down approximately 23% in Tuesday's session, trading near $7.24 after closing at $9.40 on Monday, March 23. The sharp decline follows an 11%+ surge in the prior session, with profit-taking and valuation pressure cited as primary triggers.
Shares of Circle Internet Group (CRCL) are down approximately 9% in Tuesday morning trading, extending a pullback from recent multi-month highs above $126. The primary catalyst appears to be a broad crypto-sector risk-off wave, with Bitcoin sliding below $69,000 and the Fear & Greed Index dropping to extreme fear territory.
ALM shares are indicated down about 11% in early Tuesday trading after closing the prior session at $16.93. The move comes after a powerful multi‑month rally that took the stock from below $3 to an intraday high of $22.55 earlier in March, leaving it vulnerable to profit-taking and volatility.​
LUNR shares are indicated down about 7% in Tuesday premarket trading after closing the last regular session at $20.31. The pullback follows a powerful rally driven by strong 2026 revenue guidance of $900 million–$1 billion and upbeat analyst commentary, including price target hikes and buy ratings.
MAZE shares are trading approximately 27% lower in premarket on March 25, 2026, after the company reported its highly anticipated Phase 2 HORIZON trial topline data for lead drug candidate MZE829. The catalyst is a dual announcement: Phase 2 clinical data for MZE829 in APOL1-mediated kidney disease (AMKD) alongside Q4 and full-year 2025 financial results.
ARM shares surged approximately +10% in premarket trading on March 25, 2026, hitting $148.6 from a prior close of approximately $135. The primary catalyst is Arm's historic strategic pivot: the company announced it will begin selling its own self-developed AGI CPU chips, breaking its decades-long "IP licensing only" business model.
Shares of Enliven Therapeutics (ELVN) are surging approximately +15% in premarket trading on March 25, 2026, driven by renewed investor enthusiasm around the company's advancing clinical program for ELVN-001 in chronic myeloid leukemia (CML). The stock's prior closing price on March 24, 2026 was $31.15, placing the premarket indicated price near $35.82.
AVXL shares are down approximately 29% in premarket trading on Wednesday, March 25, 2026, falling to roughly $2.97 from the prior close of $4.19. The primary catalyst is Anavex's formal withdrawal of its marketing authorization application (MAA) for blarcamesine from the European Union, announced in the early hours of March 25, 2026.